In a recent publication based on 104 patients treated for breast cancer, higher MDR1/P-gp expression was associated with a statistically significant shorter OS and progression-free time, but the authors used a method based on immunohistochemical reactions using monoclonal antibodies (Surowiak et al, 2005). This evidence concerns the gene PGP and breast cancer.